The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan

Author:

Lai Shih-Wei1,Liao Kuan-Fu2,Kuo Yu-Hung3,Hwang Bing-Fang4,Liu Chiu-Shong5

Affiliation:

1. Department of Public Health, College of Public Health, and School of Medicine, College of Medicine, China Medical University, Taichung, TaiwanDepartment of Family Medicine, China Medical University Hospital, Taichung, Taiwan

2. College of Medicine, Tzu Chi University, Hualien, Taiwan, Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan

3. Department of Research, Taichung Tzu Chi Hospital, Taichung, Taiwan

4. Department of Occupational Safety and Health, College of Public Health, China Medical University, Taichung, Taiwan

5. Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan.

Abstract

Epidemiological studies have shown that people having hyperuricemia are at increased risk of ischemic cerebrovascular disease. This research aimed to study the relation of ischemic cerebrovascular disease with benzbromarone use among persons with gout-related disorders. This was a retrospective cohort design utilizing a 2003 to 2015 national health insurance database in Taiwan. Subjects aged 20 to 99 years who already had suffered from gout-related disorders were included as eligible subjects. Eligible persons who had the benzbromarone prescription alone were selected into the benzbromarone group. Sex-matched and age-matched eligible persons who never used any urate-lowering agents were selected into the control group. An index date was set as a date of benzbromarone being prescribed. The end-point was defined as ischemic cerebrovascular disease being newly diagnosed. A hazard ratio was applied to measure the association strength between benzbromarone use and ischemic cerebrovascular disease. Totally, there were 13,398 persons in the benzbromarone group and 13,398 persons in the control group. The incidence rate of ischemic cerebrovascular disease seemed to be modestly higher in the benzbromarone group than the control group, but it did not achieve statistical significance (0.78 vs 0.75 every 100 person-years, incidence rate ratio = 1.05, 95% confidence interval = 0.94–1.16). A crude hazard ratio of ischemic cerebrovascular disease showed 1.05 in the benzbromarone group (95% confidence interval = 0.94–1.17, P = .373) comparing with the control group. No significant association can be detected between benzbromarone use and the probability of ischemic cerebrovascular disease among persons with gout-related disorders. We think that reduction of the serum uric acid by use of benzbromarone could not be related to the probability of ischemic cerebrovascular disease. Further research is suggested to clarify this issue.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference26 articles.

1. Clinical practice. Gout.;Neogi;N Engl J Med,2011

2. Diagnosis, treatment, and prevention of gout.;Hainer;Am Fam Physician,2014

3. Gout and hyperuricaemia in the USA: prevalence and trends.;Singh;Rheumatology (Oxford),2019

4. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008.;Chuang;Asia Pac J Clin Nutr,2011

5. Gout.;Perez-Ruiz;Rheum Dis Clin North Am,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3